Overview

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Otsuka Pharmaceutical Co., Ltd.